Skip Nav Destination
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
Autologous transplantation of granulocyte colony-stimulating factor–primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines
Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
Issue Archive
Table of Contents
INSIDE BLOOD
BLOOD WORK
CHEMOKINES
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
Clinical Trials & Observations
Martha Wadleigh,Paul G. Richardson,David Zahrieh,Stephanie J. Lee,Corey Cutler,Vincent Ho,Edwin P. Alyea,Joseph H. Antin,Richard M. Stone,Robert J. Soiffer,Daniel J. DeAngelo
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
Clinical Trials & Observations
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
Clinical Trials & Observations
Simona Soverini,Michele Cavo,Claudia Cellini,Carolina Terragna,Elena Zamagni,Deborah Ruggeri,Nicoletta Testoni,Patrizia Tosi,Antonio de Vivo,Marilina Amabile,Tiziana Grafone,Emanuela Ottaviani,Barbara Giannini,Delia Cangini,Francesca Bonifazi,Antonino Neri,Sonia Fabris,Sante Tura,Michele Baccarani,Giovanni Martinelli
Autologous transplantation of granulocyte colony-stimulating factor–primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization
Clinical Trials & Observations
Roberto M. Lemoli,Antonio de Vivo,Daniela Damiani,Alessandro Isidori,Monica Tani,Alessandro Bonini,Claudia Cellini,Antonio Curti,Luigi Gugliotta,Giuseppe Visani,Renato Fanin,Michele Baccarani
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
Clinical Trials & Observations
Joseph H. Antin,Haesook T. Kim,Corey Cutler,Vincent T. Ho,Stephanie J. Lee,David B. Miklos,Ephraim P. Hochberg,Catherine J. Wu,Edwin P. Alyea,Robert J. Soiffer
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Clinical Trials & Observations
Oliver W. Press,Joseph M. Unger,Rita M. Braziel,David G. Maloney,Thomas P. Miller,Michael LeBlanc,Ellen R. Gaynor,Saul E. Rivkin,Richard I. Fisher
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
Clinical Trials & Observations
Claudia D. Baldus,Stephan M. Tanner,Amy S. Ruppert,Susan P. Whitman,Kellie J. Archer,Guido Marcucci,Michael A. Caligiuri,Andrew J. Carroll,James W. Vardiman,Bayard L. Powell,Steven L. Allen,Joseph O. Moore,Richard A. Larson,Jonathan E. Kolitz,Albert de la Chapelle,Clara D. Bloomfield
Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines
Clinical Trials & Observations
Brief Report
Hisao Hirai,Hiroshi Kubo,Mutsuo Yamaya,Katsutoshi Nakayama,Muneo Numasaki,Seiichi Kobayashi,Satoshi Suzuki,Shigeki Shibahara,Hidetada Sasaki
Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)
Clinical Trials & Observations
Brief Report
HEMATOPOIESIS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
CD2 engagement induces dendritic cell activation: implications for immune surveillance and T-cell activation
Keith Crawford,Aleksandra Stark,Betsy Kitchens,Kerry Sternheim,Vassilios Pantazopoulos,Ellen Triantafellow,Zhigang Wang,Baldev Vasir,Charles E. Larsen,Dana Gabuzda,Ellis Reinherz,Chester A. Alper
Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli
Michael Jefford,Max Schnurr,Tracey Toy,Kelly-Anne Masterman,Amanda Shin,Tina Beecroft,Tsin Yee Tai,Ken Shortman,Mark Shackleton,Ian D. Davis,Phil Parente,Thomas Luft,Weisan Chen,Jonathan Cebon,Eugene Maraskovsky
Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes
Renato Zambello,Michela Falco,Mariella Della Chiesa,Livio Trentin,Davide Carollo,Roberta Castriconi,Giovanna Cannas,Simona Carlomagno,Anna Cabrelle,Thierry Lamy,Carlo Agostini,Alessandro Moretta,Gianpietro Semenzato,Massimo Vitale
Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2
Ji-yan Liu,Yu-quan Wei,Li Yang,Xia Zhao,Ling Tian,Jian-mei Hou,Ting Niu,Fen Liu,Yu Jiang,Bing Hu,Yang Wu,Jing-mei Su,Yan-yan Lou,Qiu-ming He,Yan-jun Wen,Jin-liang Yang,Bing Kan,Yong-qiu Mao,Feng Luo,Feng Peng
NEOPLASIA
PHAGOCYTES
RED CELLS
TRANSPLANTATION
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma
Brief Report
Paolo Corradini,Michele Cavo,Henk Lokhorst,Giovanni Martinelli,Carolina Terragna,Ignazio Majolino,Pinuccia Valagussa,Mario Boccadoro,Diana Samson,Andrea Bacigalupo,Nigel Russell,Vittorio Montefusco,Claudia Voena,Gosta Gahrton,the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
CORRESPONDENCE
-
Cover Image
Cover Image
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals